www.amphionplc.com
Amphion builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK.
Amphion has a significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.
Sorry, no articles available.
-
10/05/12
Amphion Innovations gets US$500,000 loan from chairman -
02/05/12
Amphion Innovations’ partner Axcess reaches milestone in patent case -
29/03/12
Amphion Innovations partner Axcess secures up to US$10 mln credit facility -
24/02/12
Amphion Innovations secures additional US$500,000 loan from chairman -
02/02/12
Amphion Innovations shares rise as DataTern patents are reinforced -
02/02/12
Amphion Innovations shares rise as DataTern patents are reinforced -
19/12/11
Amphion Innovations is significantly undervalued against its NAV, says broker -
29/09/11
Amphion Innovations moves into the black during first half -
15/08/11
Amphion Innovations: on the turnaround track -
02/08/11
Amphion Innovations swings into profit -
28/07/11
Amphion Innovations adjourns its AGM until September -
22/07/11
Amphion Innovations CEO Richard Morgan shows faith in firm with share purchase -
30/06/11
Inherent value to be “developed and extracted” at Amphion -
24/05/11
Amphion Innovations sells Myconostica for stake in Lab21 -
15/04/11
Amphion Innovations raises $0.5mln from incoming chairman Macaleer -
13/04/11
Amphion Innovations subsidiary obtains patent infringement settlements for over US$17m -
28/02/11
Amphion Innovations sees signs of life in IPO market, IP licensing revenues "improve markedly" -
06/01/11
Amphion shares soar as the company reassures on its working capital position -
05/01/11
Amphion patent settlements rake in $1.25mln; says it has enough cash to meet working capital needs -
09/12/10
Amphion Innovations gets US$500,000 loan from major shareholder -
29/11/10
Amphion Innovations partner Kromek secures US$1.5m contract from UMASS -
08/06/10
Amphion Innovations to progress IP licensing with renewed confidence -
30/03/10
Amphion Innovations CEO buys 65,000 more shares -
16/03/10
Amphion Innovations continues progress in 2009 as IP Licensing business drives growth -
15/03/10
Amphion Innovations partner Kromek raises £12.3 million to fund expansion -
03/03/10
Amphion Innovations partner WellGen's theaflavin tea extract gets positive review -
03/03/10
Amphion Innovations partner Axcess launches new wireless credential product -
25/02/10
Amphion Innovations partner PrivateMarkets appoints new sales director -
18/02/10
Charles Stanley sees Amphion Innovations’ Kromek and WellGen as leading IPO candidates in 2010 -
02/02/10
Amphion narrows full-year loss and increases revenue 22 pct -
19/01/10
Amphion partner Myconostica launches new assay in EU and Canada, appoints distributor for Sweden and Finland -
12/01/10
Myconostica secures license from Health Canada for Aspergillus diagnostic test -
23/12/09
Amphion Innovations receives further funding, DataTern signs more licensing deals worth US$4.15 mln -
21/12/09
Amphion Innovations investee WellGen in food product collaboration with RFI Ingredients -
02/12/09
Amphion Innovations appoints Katharine Cushing as strategic investment advisor based in NY -
25/11/09
Amphion Innovations to set up technology transfer unit at Kuwait University -
14/10/09
Amphion investee Myconostica launches diagnostic test for Aspergillus fungus -
09/10/09
Amphion Innovations investee Kromek’s CEO Arnab Basu named ‘Ernst & Young Entrepreneur Of The Year’ -
06/10/09
Amphion reports positive pre-clinical trial results for WellGen’s black tea concentrate -
21/09/09
Amphion pays directors’ fees with 273,976 shares -
07/09/09
Amphion investee Myconostica attracts £1.7 million in new funding
Sorry, no media files found.
